Arovella Newsletter November 2025
Welcome all to another instalment of our newsletter. The year end draws near and we are excited to finish the year off strong. The Company is in a great position from a development perspective and financial perspective. Please read on to hear the latest updates from the Company, and as always, we would first like to acknowledge the unwavering support of all our shareholders, thank you. Since we last checked in, it has been a productive time on multiple fronts. Our assets are developing nicely, we have expanded our research capability further, and we have continued our strategic lens to in-licensing technologies to enhance the pipeline for tumours of high unmet need.
Recent Highlights:
Continued advancing ALA-101 towards a first-inhuman clinical trial with appointment of SAPRO as CRO
Held successful Type D meeting with FDA
Established internal lab at Jumar Bioincubator
Continued to expand the team appointing board member Dr Andrew Nash and scientists Dr Alfie Baker and Dr Sarah Sandford
CLDN18.2 CAR-T cells shown to robustly eliminate pancreatic cancer cells that express CLDN18.2 in vitro
Exercised the Exclusive Option with Baylor College of Medicine for two new CARs
